Anti-CD22 CAR T cell therapy (Shanghai GeneChem)

抗CD22嵌合抗原T细胞疗法

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD22 CAR T cell therapy (Shanghai GeneChem)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionImmunostimulantsCD22 modulators
TargetsCD22
Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Genechem Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Genechem Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A